HEALTHSTORY 511· JULY 7, 2026

Vertex Pharmaceuticals to Buy Crinetics Pharmaceuticals for $10 Billion in Rare Disease Deal

Vertex Pharmaceuticals announced Monday it will acquire Crinetics Pharmaceuticals for $10 billion, or roughly $85 per share, adding a commercial rare-disease therapy and additional pipeline candidates to its portfolio. The deal centers on…

NDNewsDialy Desk2 MIN READ

SOURCE

statnews.com

← PREVIOUS STORY 510Fred Karlinsky of Greenberg Traurig Named Chair-Elect of Leadership Florida Board NEXT STORY 512 →UMD Smith School Study Says America's Infrastructure Gap Is a Design Problem, Not a Money Problem

Keep reading

More from the desk.

07HEALTH

FDA clears first CELMoD drug for blood cancer as a $6.7 billion shareholder lawsuit returns to court

Multiple myeloma, a blood cancer, now has a new oral treatment approved by U.S. regulators. The Food and Drug Administration cleared Zenbexus, made by Bristol Myers Squibb, as the first drug in a new class called CELMoDs and the first drug…

health2 MIN

45HEALTH

Autoimmune research pioneer Georg Schett co-founds his first biotech, choosing antibody therapies over CAR-T

Georg Schett, the German scientist who spent five years demonstrating that CAR-T therapy, a treatment that engineers a patient's own immune cells to target and eliminate the source of disease, can reset the immune system in autoimmune…

health2 MIN

61HEALTH

Splitting the MMR vaccine risks more missed doses and more sick children, history suggests

Separating the MMR vaccine into individual shots is likely to produce more missed doses and more sick kids. The MMR is a single injection covering measles, mumps, and rubella. It is now the target of a White House executive order

health2 MIN

Tomorrow · 06:00

Start tomorrow already ahead.

Five stories, a two-minute read, zero noise — the world before your first coffee.

Get the 6AM brief Back to the desk